PAB Tri-Axis Dominant-Primary Series IV-NP

Brassica nigra

Black Mustard

Tier IVPAB Tri-Axis Dominant-Primary Series

Target Trait

2.38×

fold-change

Sharp-dominant tri-axis A+B modulated fold-change

Technical Specifications

SKU

SS-F-M3-01595

Genomic Edits

GC Content

48.7%

Construct Length

6,133 bp

Promoter System

Lipid nanoparticle / Ubiquitin

Expression System

Nanoparticle delivery

Host Strain

LNP-mediated

Receptor Target

TRPA1 + Polyphenol-astringency axis + TAS2R38 (suppression)

IFI Score

238

Pathway Edits

TRPA1 pathway primary gene cluster for sharp (IFI-P) tri-axis component
Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
Tri-axis metabolic flux partitioning hub for concurrent PAB pathway operation
Cross-pathway regulatory circuit for sharp-dominant PAB triple-axis expression
Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPA1, Polyphenol-astringency axis, and TAS2R38 (suppression) pathways simultaneously engineeredSharp-dominant tri-axis expression strategy (PAB) with cross-pathway flux managementLNP-mediated delivery of triple-axis mRNA panel for transient expression profiling

IFI Subscale Profile

IFI Profile

IFI-S

—

IFI-U

—

IFI-B

—

IFI-K

—

IFI-C

—

IFI-P

—

IFI-A

—

IFI-F

—

Use Case

Tier IV PAB triple-axis construct for advanced multi-modal sensory architecture combining sharp, astringency, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$4249 · Tier IV License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-M All Modalities